# Click-activated prodrugs (bioorthogonal drug activation in the body)

Source: https://onco.cc/technologies/click-activated-prodrugs/  
OnCo record `click-activated-prodrugs` (Technology). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Two ingredients are given separately: one is placed at or guided to the tumour, the other is an inactive form of a cancer drug sent through the blood. Where they meet, a fast chemical reaction releases the active drug. One early trial in people showed the chemistry works in the body but did not shrink more tumours than the ordinary drug.

## Summary

Click-activated prodrugs split a cancer medicine into two parts that do nothing alone. An activator is first put at the tumour, either by injecting it into a lesion or by attaching it to something that binds a tumour antigen. An inert, chemically capped form of a cytotoxic drug is then given into a vein. The two carry matched reactive groups, a tetrazine and a trans-cyclooctene, which react with each other and with little else in the body (a bioorthogonal, or click, reaction). In the published designs the reaction captures the capped drug at the activator and the cap then falls away, releasing the active drug at that site.

The chemistry was recognised by the 2022 Nobel Prize in Chemistry, awarded to Carolyn Bertozzi, Morten Meldal and Barry Sharpless for the development of click chemistry and bioorthogonal chemistry; the prize announcement noted that bioorthogonal reactions were being used to improve the targeting of cancer medicines in clinical trials.

The first reported use in patients was Shasqi's SQ3370: a tetrazine-modified hyaluronate biopolymer injected into one tumour, followed by daily infusions of a trans-cyclooctene-modified doxorubicin. Its phase 1/2a trial (NCT04106492) gave doxorubicin-equivalent doses up to 15 times the conventional dose per cycle with no protocol-defined dose-limiting toxicity, and the authors measured rapid release of active doxorubicin at every dose level. In the 14 patients with soft tissue sarcoma treated in phase 2a, two had an unconfirmed objective response (14.3 per cent), which the authors describe as comparable to standard doxorubicin, and the trial was stopped because the prespecified bar of a response rate above standard doxorubicin was not met. So the trial supports the chemistry and the tolerability, and does not show better tumour control.

A second form replaces the injected biopolymer with a tumour-binding protein carrying the activator, which removes the need for an injectable lesion. Shasqi has published this in mice with a HER2-binding antibody fragment and a capped MMAE, and its pipeline lists CEACAM5-targeted programmes that have not reached the clinic. Tagworks Pharmaceuticals uses the reaction the other way round, in an approach it calls Click-to-Release: its TGW101 is a diabody drug conjugate whose payload is cut free by a separately given small-molecule trigger, in a phase 1 trial registered as NCT06959706. No medicine of this kind is approved anywhere.

## Fields

- Kind: Technology
- Status: phase-2
- Last checked: 2026-11-16
- Also known as: click chemistry prodrug activation; bioorthogonal prodrug activation; click-activated protodrugs; CAPAC; Click Activated Protodrugs Against Cancer; click-to-release; in vivo click chemistry; tetrazine ligation
- Tags: frontier
- Principle: An inverse electron-demand Diels-Alder reaction between a tetrazine and a trans-cyclooctene (TCO). In Shasqi's design the tetrazine sits on the tumour-localised activator and the TCO caps the drug, attenuating its activity; the reaction at the tumour captures the capped drug and is followed by release of the native drug. Activation depends on the two components meeting, not on tumour enzymes, acidity, oxygen level or uptake into the cell.
- Since: 2020
- Strengths: Activation does not rely on the tumour cell taking the drug in or on tumour enzymes, so targets that do not internalise are open to it (stated by the developers; shown so far in animal models).; The targeting part carries no drug, so none is shed from it in healthy tissue on the way to the tumour (the developers' argument for the design).; In the one human trial, doxorubicin-equivalent doses up to 15 times the conventional dose per cycle were given with no protocol-defined dose-limiting toxicity.; Modular: the same activator has been paired with capped forms of doxorubicin, paclitaxel, etoposide, gemcitabine and MMAE in laboratory work.
- Limitations: The only efficacy data in people are from 14 patients; the response rate was comparable to standard doxorubicin and the trial was stopped on that prespecified criterion.; The form tested in people needs a tumour that can be injected, and treats distant disease only through whatever drug or immune effect reaches it.; Two products must be made, dosed and timed, and the trial was neither randomised nor compared with doxorubicin directly.; The antigen-targeted forms that would remove the need for injection have no published human data.

## Notes

- "Protodrug" is Shasqi's word for the capped drug; OnCo uses prodrug except where quoting.
- Shasqi describes itself as the first company to use click chemistry in patients (shasqi.com, read 16 November 2026); the Clinical Cancer Research paper calls SQ3370 the first demonstration of click chemistry within the human body in a clinical setting. OnCo repeats the claim as theirs and has not checked it against every registry.

## Sources

- Nobel Prize in Chemistry 2022, press release: https://www.nobelprize.org/prizes/chemistry/2022/press-release/
- Srinivasan et al., Clinical Cancer Research 2025 (SQ3370, preclinical to first-in-human): https://doi.org/10.1158/1078-0432.CCR-24-2539
- Chawla et al., medRxiv 2025 (SQ3370 phase 1/2a, preprint): https://doi.org/10.1101/2025.06.02.25328445
- Wu et al., Chemical Science 2021 (the platform chemistry): https://doi.org/10.1039/d0sc06099b
- Shasqi: how the CAPAC platform works: https://www.shasqi.com/our-platform
- ClinicalTrials.gov NCT04106492 (SQ3370): https://clinicaltrials.gov/study/NCT04106492
- Tagworks Pharmaceuticals: Click-to-Release: https://www.tagworkspharma.com/
- ClinicalTrials.gov NCT06959706 (Tagworks TGW101): https://clinicaltrials.gov/study/NCT06959706

## Connected records

- fronts: [Antibody-Drug Conjugates](https://onco.cc/fronts/adcs/), [Chemotherapy](https://onco.cc/fronts/chemotherapy/)
- technologies: [Antibody-drug conjugate (ADC)](https://onco.cc/technologies/adc/), [Cytotoxic chemotherapy](https://onco.cc/technologies/cytotoxic-chemotherapy/), [Masked / conditionally active ADC](https://onco.cc/technologies/masked-adc/)
- drugs: [SQ3370](https://onco.cc/drugs/sq3370/)
- companies: [Shasqi](https://onco.cc/companies/shasqi/), [Tagworks Pharmaceuticals](https://onco.cc/companies/tagworks-pharmaceuticals/)
- terms: [MMAE](https://onco.cc/terms/mmae/), [Payload (ADC)](https://onco.cc/terms/payload/), [Prodrug](https://onco.cc/terms/prodrug/), [Therapeutic index (therapeutic window)](https://onco.cc/terms/therapeutic-index/)
- trials: [SQ3370 in advanced solid tumours and soft tissue sarcoma (SQ3370-001, phase 1/2a)](https://onco.cc/trials/nct04106492/)
- key papers: [A click-activated MMAE prodrug switched on by an injected biopolymer or by a HER2-binding antibody fragment](https://onco.cc/key-papers/paper-mcfarland-auristatin-protodrug-click-activation-acs-cent-sci-2023/), [An implantable biomaterial that captures small molecules by click chemistry in the body](https://onco.cc/key-papers/paper-mejia-oneto-implantable-biomaterial-click-chemistry-acta-biomater-2014/), [Click Activated Protodrugs Against Cancer: local capture and activation of capped chemotherapy by a tetrazine biopolymer](https://onco.cc/key-papers/paper-wu-click-activated-protodrugs-local-capture-chem-sci-2021/), [Local drug activation by bioorthogonal chemistry: an implanted hydrogel and a systemic doxorubicin prodrug in a sarcoma xenograft](https://onco.cc/key-papers/paper-mejia-oneto-local-hydrogel-systemic-prodrug-sarcoma-acs-cent-sci-2016/), [SQ3370 from preclinical evaluation to a first-in-human dose-escalation trial: the first click chemistry-based cancer therapeutic](https://onco.cc/key-papers/paper-srinivasan-sq3370-preclinical-to-first-in-human-clin-cancer-res-2025/), [SQ3370 in mice with two tumours: responses in the injected and the non-injected lesion](https://onco.cc/key-papers/paper-srinivasan-sq3370-injected-and-non-injected-lesions-adv-ther-2021/), [SQ3370 phase 1/2a results in advanced solid tumours and soft tissue sarcoma (preprint)](https://onco.cc/key-papers/paper-chawla-sq3370-phase-1-2a-advanced-solid-tumours-medrxiv-2025/)

---
JSON: https://onco.cc/api/v1/entities/click-activated-prodrugs.json